ImmunityBio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$225.7Mnext fiscal year
FY EPS (est.)
-$0.92next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| PDUFA Action Date for sBLA (ANKTIVA plus BCG in Papillary NMIBC) | 6 Jan 2027 |
Monitoring Framework
Key Performance Indicators
ANKTIVA Net Product Revenue Quarterly44.2M
Consolidated Cash, Cash Equivalents, and Marketable Securities Quarterly380.9M
Watch Items
- FDA Supplemental BLA (sBLA) Decision for ANKTIVA plus BCG in Papillary NMIBCTrigger: PDUFA Date set for January 6, 2027Action: Monitor regulatory communications and FDA feedback leading up to the PDUFA action date.
- Douglas v. ImmunityBio, Inc. Securities Class Action LitigationTrigger: Class period January 19, 2026 to March 24, 2026; Lead Plaintiff deadline May 26, 2026Action: Track court filings, motions to dismiss, and potential financial reserve requirements or settlement discussions.
- FDA Warning Letter Compliance and Corrective ActionsTrigger: FDA Warning Letter issued March 13, 2026 (publicized March 24, 2026)Action: Review company's promotional materials, corrective marketing campaigns, and correspondence with the FDA's Office of Prescription Drug Promotion (OPDP).
Research as of 2 Sep 2026